当前研究新肌松药的注意力仍集中于苄异喹啉(benzylisoquinolines)和甾类化合物。这两类肌松药神经肌肉阻滞的效应强,没有其它肌松药的典型副作用(例如阻滞迷走神经和神经节以及组胺释放等),而且代谢和消除得也比较快。因此,作用时限短,不蓄积,自主呼吸恢复得也快,很少有残余的阻滞作用,必要时也只需用小剂量抗胆硷脂酶药。一、当前对埃屈寇林和万可松的一些看法由于这两种新肌松药的中等作用时限,所以扩大了临床使用范围。万可松(去甲本可松或去甲潘侃朗宁)是对心血管几乎没有影响的非去极化肌松药,因此有较好的前途。埃屈寇林是能充分降解成无活性代谢物的非去极化肌松药,因此蓄积作用和作用时 Attention is still being focused on benzylisoquinolines and steroids. These two types of muscle relaxants have strong neuromuscular blockade effects without the typical side effects of other muscle relaxants (such as blocking vagal and ganglionic as well as histamine release, etc.) and are metabolized and eliminated more rapidly. Therefore, the role of time is short, no accumulation of spontaneous breathing recovered too fast, very few residual blockade, if necessary, only a small dose of anticholinergic drugs. First, some of the current views of Eclocorne and Vancomycin have broadened the range of clinical use due to the moderating effect of these two new muscle relaxants. Vancomycin (desmetonic or norepinephrine) is a non-depolarizing muscle relaxant that has little effect on cardiovascular activity and therefore has a good future. Eclogulin is a non-depolarizing muscle relaxant that can be fully degraded into inactive metabolites, so when accumulating and acting